Morgan Stanley reiterated their overweight rating on shares of DBV Technologies S.A. (NASDAQ:DBVT) in a report issued on Friday, October 6th. Morgan Stanley currently has a $72.00 price objective on the stock, up from their previous price objective of $70.00.
Several other equities research analysts have also recently issued reports on the company. Citigroup Inc. raised their target price on DBV Technologies from $43.00 to $57.00 and gave the stock a buy rating in a research note on Monday, October 2nd. Zacks Investment Research cut DBV Technologies from a buy rating to a hold rating in a research note on Friday, September 29th. ValuEngine cut DBV Technologies from a hold rating to a sell rating in a research note on Tuesday, September 26th. Jefferies Group LLC restated a buy rating and set a $51.00 price target on shares of DBV Technologies in a research report on Tuesday, September 12th. Finally, Leerink Swann raised their price target on DBV Technologies from $54.00 to $60.00 and gave the stock an outperform rating in a research report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $56.29.
DBV Technologies (NASDAQ:DBVT) opened at 47.89 on Friday. The firm’s 50-day moving average is $44.74 and its 200-day moving average is $39.32. The stock’s market capitalization is $2.20 billion. DBV Technologies has a 12-month low of $31.87 and a 12-month high of $50.57.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/morgan-stanley-reaffirms-overweight-rating-for-dbv-technologies-s-a-dbvt/1703394.html.
A number of institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of DBV Technologies during the second quarter worth about $222,000. Victory Capital Management Inc. acquired a new position in DBV Technologies in the 1st quarter valued at about $303,000. Airain ltd purchased a new stake in DBV Technologies in the 2nd quarter valued at approximately $333,000. Sit Investment Associates Inc. purchased a new stake in DBV Technologies in the 2nd quarter valued at approximately $698,000. Finally, Jane Street Group LLC purchased a new stake in DBV Technologies in the 1st quarter valued at approximately $853,000. Institutional investors own 45.52% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with our FREE daily email newsletter.